ArticleClinical rheumatology2026
SLA and DDX60L as potential diagnostic biomarkers for subclinical atherosclerosis in systemic lupus erythematosus: a transcriptomic and clinical validation study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSystemic lupus erythematosus (SLE) patients face a 5-tenfold increased risk of atherosclerosis (AS), with subclinical lesions often progressing asymptomatically until life-threatening cardiovascular events occur. This study aimed to identify reliable molecular biomarkers for the early detection of SLE-associated AS.
methodsTranscriptomic datasets (GSE154851 for SLE, GSE100927 for AS) were retrieved from the Gene Expression Omnibus (GEO) database. Weighted gene co-expression network analysis (WGCNA) and differential gene expression (DEG) analysis were performed to screen disease-related genes. Three machine learning algorithms (LASSO, SVM-RFE, Random Forest) were integrated to identify core diagnostic genes. The diagnostic efficacy was validated using external datasets (GSE37356, GSE43292) and clinical peripheral blood samples via quantitative real-time PCR (qPCR). Gene set enrichment analysis (GSEA) and CIBERSORT immune infiltration analysis were conducted to explore the underlying molecular mechanisms.
resultsA total of 47 shared pathogenic genes were identified between SLE and AS. Subsequent screening by machine learning algorithms pinpointed DDX60L and SLA as core diagnostic biomarkers. Both genes exhibited robust diagnostic performance in external datasets: DDX60L had an AUC of 0.761 (SLE) and 0.731 (AS), while SLA showed an AUC of 0.971 (SLE) and 0.748 (AS). qPCR validation confirmed a distinct expression gradient (healthy < SLE < AS < SLE + AS). GSEA revealed enrichment of the JAK-STAT signaling pathway, immune regulation, and metabolic pathways (folate biosynthesis, lysine degradation) associated with these two genes. Immune infiltration analysis indicated that DDX60L and SLA expression correlated with the abundance of pro-atherogenic immune cells (neutrophils, M0 macrophages).
conclusionDDX60L and SLA serve as reliable diagnostic biomarkers for subclinical AS in SLE patients, potentially regulating disease progression via the JAK-STAT pathway and immune cell dysregulation. These findings provide a theoretical basis for early risk stratification and targeted intervention in high-risk SLE populations.. Key Points • DDX60L and SLA are identified as novel diagnostic biomarkers for subclinical atherosclerosis in SLE patients. • The two genes exhibit a distinct expression gradient correlating with disease severity (Healthy healthy< SLE < AS < SLE+AS) • DDX60L and SLA may regulate SLE-associated AS progression via the JAK-STAT signaling pathway and immune cell dysregulation. • The findings provide a theoretical basis for early screening and prevention of cardiovascular complications in SLE patients.
Indexed as
Identifiers
42154423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.